Israeli medical startup AISAP has been recognized by Fast Company as one of the world's most innovative companies for 2025, securing fourth place globally in the healthcare category.
by 
Israeli medical technology startup AISAP has earned global recognition from Fast Company, securing fourth place in the healthcare category of the World’s Most Innovative Companies 2025 list. This prestigious accolade underscores the transformative impact of AISAP’s artificial intelligence-driven cardiac diagnostic platform on modern medicine.
Pioneering AI-Powered Cardiac Diagnostics
Founded by Adiel Am-Shalom, a former officer in Israel’s elite 8200 intelligence unit, AISAP is backed by leading medical professionals, including Professor Ehud Raanani, Professor Robert Klempner, and Professor Ehud Schwammenthal. To date, the company has raised approximately $13 million from prominent investors such as Harel Insurance, Shoni Health, and former Mossad director Tamir Pardo.
AISAP’s flagship product, AISAP CARDIO, is the world’s first real-time AI-powered cardiac diagnostic platform. Designed to provide immediate and highly accurate detection of structural heart diseases and heart failure, this groundbreaking technology recently received FDA approval—marking a major milestone in AI-driven medical diagnostics.
Transforming Patient Care with Real-Time Insights
Adiel Am-Shalom, CEO of AISAP, emphasized the significance of this recognition: “This is a strong validation that our product has the potential to revolutionize medicine worldwide and save countless lives through real-time, precise diagnostics.”
Co-founder Professor Ehud Raanani echoed this sentiment, highlighting the company’s commitment to innovation and improving patient outcomes on a global scale.
AISAP’s AI technology enables real-time ultrasound image analysis directly at the patient’s bedside. Seamlessly integrating with existing hospital systems, it eliminates the need for additional hardware. The platform’s AI algorithms—trained on hundreds of thousands of echocardiograms and more than 24 million video segments—have been rigorously validated in clinical trials conducted by leading institutions, including Harvard Medical School’s Mass General Brigham Digital Clinical Research, Mayo Clinic, Thomas Jefferson University Hospital, and Stony Brook University Hospital.
Clinical Impact and Rapid Adoption
The effectiveness of AISAP’s technology is evident in real-world clinical settings. In practice, the system has led to significant findings in 50% of scans, influenced treatment decisions in 30% of cases, and prompted urgent interventions in 5% of patients. Over the past year, the company has experienced exponential growth, with a fivefold increase in its customer base and a tenfold rise in its user base.
Currently operational in emergency rooms and internal medicine departments of leading hospitals in Israel and the United States, AISAP’s platform has already benefited tens of thousands of patients.
A Vision for the Future
AISAP envisions a future where every physician is equipped with a portable ultrasound device, revolutionizing cardiac diagnostics and patient care worldwide. With its cutting-edge AI-powered technology, the company is poised to reshape the landscape of cardiovascular medicine, enhancing early detection and treatment outcomes for patients across the globe.
